BioMarin Pharmaceutical Inc. (BMRN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 12:56PM EDT. Market open.
| Previous Close | 89.49 |
| Open | 90.03 |
| Bid | 91.76 x 100 |
| Ask | 91.95 x 100 |
| Day's Range | 89.99 - 92.10 |
| 52 Week Range | 76.02 - 99.56 |
| Volume | |
| Avg. Volume | 1,403,535 |
| Market Cap | 17.434B |
| Beta (5Y Monthly) | 0.32 |
| PE Ratio (TTM) | 105.59 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
- Zacks
Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for BioMarin (BMRN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
- Zacks
Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
© 2024 Yahoo. All rights reserved.